K. Daveson1, J. Turnidge1, K. Meleady1
1 Australian Commission on Safety and Quality in Health Care, GPO Box 5480, Sydney NSW 2001, AURA@safetyandquality.gov.au
The Australian Commission on Safety and Quality in Health Care (the Commission) established AURA to provide coordinated surveillance of antimicrobial resistance (AMR) and antimicrobial use (AU) across acute and community sectors in Australia. The Commission routinely publishes analyses of AURA data to inform policies and strategies to prevent and contain AMR and improve antimicrobial use.
The Commission works with a number of surveillance partner programs which have provided the foundations for AURA, including the Australian Group on Antimicrobial Resistance (AGAR), Queensland Health to provide the base for the Australian Passive AMR Surveillance (APAS), National Antimicrobial Prescribing Surveys (NAPS), and the National Antimicrobial Utilisation Surveillance Program (NAUSP).
Additional data are used to enhance AURA surveillance and support development of reports such as AURA 2017. Data are provided by Sullivan Nicolaides Pathology, the NPS MedicineWise MedicineInsight program, Australian Government and state and territory notifiable diseases systems, the Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme.
AURA data is widely promulgated to inform patient safety programs focused on infection prevention and control and antimicrobial stewardship. Participation in AURA and the active use of AURA data support the demonstration of compliance with the National Safety and Quality in Health Care Standards, particularly the Preventing and Controlling Healthcare-Associated Infections Standard.
After three full years of operation, AURA surveillance data are now able to be used to identify trends in antimicrobial use and resistance, and highlight areas for improved patient safety by preventing and controlling; findings from the latest AURA analyses and reports will be presented.